Skip to contentpdufa.bio

miv-cel (mivocabtagene autoleucel, KYV-101)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

miv-cel (mivocabtagene autoleucel, KYV-101) is a Kyverna Therapeutics, Inc. program in stiff person syndrome. Its next catalyst is a Readout in Dec 2026.

KYTX catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: stiff person syndrome. Sponsor: Kyverna Therapeutics, Inc. (KYTX). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Dec 2026KYTX

Questions

When is miv-cel (mivocabtagene autoleucel, KYV-101)'s next FDA decision or readout?

The next tracked catalyst for miv-cel (mivocabtagene autoleucel, KYV-101) is a Readout in Dec 2026.

What happened at miv-cel (mivocabtagene autoleucel, KYV-101)'s most recent FDA decision?

No FDA decision for miv-cel (mivocabtagene autoleucel, KYV-101) is in our archive yet.

What is miv-cel (mivocabtagene autoleucel, KYV-101) used for?

In our records miv-cel (mivocabtagene autoleucel, KYV-101) is under review or in development for stiff person syndrome.

Who makes miv-cel (mivocabtagene autoleucel, KYV-101)?

Kyverna Therapeutics, Inc. (KYTX).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.